

HARRIS & HARRIS GROUP INC /NY/  
Form 8-K  
April 08, 2014

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported):

April 8, 2014 (April 8, 2014)

**HARRIS & HARRIS GROUP, INC.**

(Exact name of registrant as specified in its charter)

**New York**                      **0-11576**                      **13-3119827**  
(State or other jurisdiction of    (Commission File    (IRS Employer

incorporation)                      Number)                      Identification No.)

**1450 Broadway  
New York, New York 10018**

(Address of principal executive offices and zip code)

**(212) 582-0900**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On April 8, 2014, Harris & Harris Group, Inc. (the "Company") noted the announcement by portfolio company, Mersana Therapeutics, Inc., that it has entered into a collaboration agreement with Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited to develop next-generation Fleximer® antibody-drug conjugates. The Company's press release is attached hereto as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits.**

(a) Not applicable.

(b) Not applicable.

(c) Not applicable.

(d) Exhibits.

**Exhibit No. Description**

99.1 Press Release dated April 8, 2014

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 8, 2014 HARRIS & HARRIS  
GROUP, INC.

By: /s/ Daniel B. Wolfe  
Daniel B. Wolfe  
President

**EXHIBIT INDEX**

**Exhibit No. Description**

99.1 Press Release dated April 8, 2014